Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MiMedx Group, Inc.
  6. Summary
    MDXG   US6024961012

MIMEDX GROUP, INC.

(MDXG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
6.16(c) 6.26(c) 6.25(c) 6.33(c) 6.07 Last
1 288 370 1 357 150 1 109 724 675 148 964 554 Volume
+3.53% +1.62% -0.16% +1.28% -4.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 251 M - -
Net income 2021 -30,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -22,2x
Yield 2021 -
Sales 2022 271 M - -
Net income 2022 -7,25 M - -
Net Debt 2022 - - -
P/E ratio 2022 -72,8x
Yield 2022 -
Capitalization 680 M 680 M -
Capi. / Sales 2021 2,71x
Capi. / Sales 2022 2,51x
Nbr of Employees 735
Free-Float 96,4%
More Financials
Company
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform... 
Read more
More about the company
Ratings of MiMedx Group, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MIMEDX GROUP, INC.
09/14MIMEDX : HC Wainwright Adjusts Price Target for MiMedx Group to $8.50 From $20, Maintains ..
MT
09/13US Stocks Start Week Mostly Higher; Blue Chips Lead While Nasdaq Lags
MT
09/13Health Care Stocks Still Adding to Afternoon Slide
MT
09/13Top Midday Decliners
MT
09/13Health Care Stocks Slipping Monday Afternoon
MT
09/13MIMEDX : Amniotic Tissue Failed to Meet Primary Endpoints in Two Trials; Shares Plunge
MT
09/13Health Care Stocks Up Slightly in Premarket Monday Activity
MT
09/13Top Premarket Decliners
MT
09/13MIMEDX : Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologi..
PU
09/13MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
09/13MIMEDX : Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary..
AQ
09/13Mimedx Reports Top-Line Data from Two Late-Stage Musculoskeletal Trials with Proprietar..
CI
09/08MIMEDX Announces Effectiveness of Shelf Registration Statement
GL
09/07MIMEDX : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AQ
08/30MIMEDX : Announces Filing Of Shelf Registration Statement With Securities And Exchange Com..
AQ
More news
News in other languages on MIMEDX GROUP, INC.
09/13Les actions américaines commencent la semaine en grande partie à la hausse ; les Blue C..
09/13Les actions du secteur de la santé continuent de s'enfoncer dans l'après-midi
09/13Les actions du secteur de la santé en baisse lundi après-midi
09/13Le tissu amniotique de MiMedx n'a pas satisfait aux critères d'évaluation primaires dan..
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 6,07 $
Average target price 16,17 $
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-30.29%709
MODERNA, INC.291.35%165 027
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.34.48%69 209
REGENERON PHARMACEUTICALS28.14%64 363